The recent acquisitions of Ergomed and Instem underscore an emerging trend: private equity entities seeking out undervalued UK life sciences firms that have been constrained by AIM’s insufficient capital resources.
The recent acquisitions of Ergomed and Instem underscore an emerging trend: private equity entities seeking out undervalued UK life sciences firms that have been constrained by AIM’s insufficient capital resources.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Proposed US$125 million financing Posting of Circular and Notice of Extraordinary General Meeting